|
Abnormal behavior
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Homozygous Slc33a1<sup>S113R</sup> mutant mice were embryonic lethal, whereas heterozygous Slc33a1 mutant mice (Slc33a1<sup>wt/mut</sup>) exhibited behavioral abnormalities and central neurodegeneration, which is consistent with hereditary spastic paraplegia (HSP) phenotypes.
|
27935820 |
2017 |
|
Absent speech
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Acute Cerebrovascular Accidents
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The results of this study show no relationship between the A1166C polymorphism in the AT1 gene and acute stroke in the Turkish population.
|
23480670 |
2013 |
|
Acute Coronary Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Autoantibodies targeting AT1 receptor from patients with acute coronary syndrome upregulate proinflammatory cytokines expression in endothelial cells involving NF-κB pathway.
|
25762441 |
2014 |
|
Acute myocardial infarction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In 82 coronary artery disease (CAD) patients and healthy controls (CTL), expressions of angiotensin I-converting enzyme (ACE), angiotensin AT1 receptor and DC-specific ICAM-3-grabbing nonintegrin (DC-SIGN) on DCs were measured by western-blot: CAD patients had an increased expression of ACE, AT1 receptor and DC-SIGN compared to controls especially in acute myocardial infarction (AMI).
|
19669395 |
2009 |
|
Adenocarcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The RT-PCR showed that AT1 receptor expression in well-differentiated adenocarcinoma was higher than that in poorly differentiated adenocarcinoma.
|
16369744 |
2005 |
|
Adenoma
|
0.020 |
GeneticVariation
|
group |
BEFREE |
We conclude that activating mutations of the AT1 receptor are not a major cause of the development of adrenal adenomas, if at all.
|
9330590 |
1997 |
|
Adenoma
|
0.020 |
GeneticVariation
|
group |
BEFREE |
In patients with aldosterone-producing adenomas either responsive or unresponsive to the renin-angiotensin system, no differences were detected using SSCP analysis in the coding region of the AT1 receptor gene in peripheral blood or tumour tissue.
|
8582102 |
1996 |
|
Adrenal Gland Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The possible involvement of AT(1) receptors in human disease has been investigated by examining the role of AngII receptors in adrenal tumours.
|
21143284 |
1996 |
|
Adrenal Gland Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Therefore, we searched by sequence analysis of the coding region of AT1 receptor gene for activating mutations and genetic polymorphisms in 56 human adrenal tumors (16 aldosterone-producing adenomas, 10 cortisol-producing adenomas, 1 aldosterone-producing carcinoma, and 29 incidentalomas).
|
9330590 |
1997 |
|
Adrenal Gland Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
In contrast, in secondary hypertension both platelets and mononuclear leucocytes AT1 receptor mRNA, which were elevated, were reduced after removal of the adrenal tumour or correction of stenosis of the renal artery.
|
7868875 |
1994 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
We studied the ability of the AT1 receptor antagonist losartan to cure or prevent AD hallmarks in aged (~18months at endpoint, 3months treatment) or adult (~12months at endpoint, 10months treatment) human amyloid precursor protein (APP) transgenic mice.
|
24807206 |
2014 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
We obtained the evidence that transient brief cerebral ischemia deteriorated cognitive impairment in AD model through AT1 receptor.
|
27572961 |
2017 |
|
Amyotrophic Lateral Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
SLC33A1 is associated with neurodegenerative disorders such as sporadic amyotrophic lateral sclerosis (ALS) and Spastic Paraplegia 42, in the Chinese population.
|
23506891 |
2013 |
|
Amyotrophic Lateral Sclerosis, Sporadic
|
0.010 |
Biomarker
|
disease |
BEFREE |
SLC33A1 is associated with neurodegenerative disorders such as sporadic amyotrophic lateral sclerosis (ALS) and Spastic Paraplegia 42, in the Chinese population.
|
23506891 |
2013 |
|
Anxiety
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, AT1 receptor antagonists-induced anti-anxiety effects are associated with up-regulation of AT2 receptors in the brain suggesting that the centrally acting AT2 receptor agonists may serve as potential anxiolytic agents.
|
23892268 |
2013 |
|
Anxiety Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Moreover, AT1 receptor antagonists-induced anti-anxiety effects are associated with up-regulation of AT2 receptors in the brain suggesting that the centrally acting AT2 receptor agonists may serve as potential anxiolytic agents.
|
23892268 |
2013 |
|
Aortic Aneurysm, Abdominal
|
0.010 |
Biomarker
|
disease |
BEFREE |
This article is to review our current understanding of angiotensin II (Ang II) and its type 1 receptor (AT1) in AAA pathogenesis as well as the translational potential of AT1 receptor blocker (ARB) treatment for treating clinical AAA disease.
|
29359665 |
2018 |
|
Aortic Stiffness
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
In this review, it will be shown that (i) converting-enzyme inhibition prevents the accumulation of aortic collagen in hypertensive rats independently of blood pressure changes, (ii) prevention of aortic collagen accumulation in hypertensive rats is obtained through blockade of angiotensin II formation involving AT1 receptors, and (iii) in hypertensive humans, increased aortic stiffness is associated with AGTR1 receptor polymorphism independently of age and blood pressure.
|
8946073 |
1996 |
|
Aortic Stiffness
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
It has been reported that a polymorphism of the AT1 receptor gene (an A/C transversion at position 1166) may be associated with cardiovascular phenotypes, such as arterial blood pressure and aortic stiffness, that underlie a condition of increased cardiovascular risk.
|
8952599 |
1996 |
|
Arteriosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Elevated levels of crosslinked AT1 receptor dimers on monocytes could sustain the process of atherogenesis, because inhibition of angiotensin II generation or of intracellular factor XIIIA activity suppressed the appearance of crosslinked AT1 receptors and symptoms of atherosclerosis in ApoE-deficient mice.
|
15507206 |
2004 |
|
Arteriosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Agonistic autoantibodies against angiotensin II type 1 (AT1) receptor (AT1-AAs) have been demonstrated to be pro-inflammatory and contribute to the progression of atherosclerosis.
|
31595199 |
2019 |
|
Arteriosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
To clarify how AT1 receptor antagonists reduce atherosclerosis, the effect of irbesartan on atherosclerotic lesion development was determined in low-fat, chow-fed apolipoprotein (Apo) E-deficient mice.
|
11486244 |
2001 |
|
Arteriosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
In the present study, we compared the effects of eprosartan, an AT(1) receptor inhibitor, with the diuretic hydrochlorothiazide in a group of newly diagnosed hypertensive patients with multiple risk factors for atherosclerosis.
|
11897210 |
2002 |
|
Arteriovenous fistula
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Arteriovenous fistula patency associated with angiotensin-converting enzyme I/D polymorphism and ACE inhibition or AT1 receptor blockade.
|
19142023 |
2009 |